

Yahya Awaji Madkhali



EDUCATION

- 2021 **Phd** in Biomedical Science, Hull University, Hull, UK.
- 2016
- 2015 **MSc** *In Biomedical Science, Nottingham Trent University,*
- 2014 *Nottingham, UK.*
- 2013 learning English as a second language, Georgia
- 2012 Tech English Institute, Atlanta, USA.
- 2007 **BSc** in Medical Technology, King Abdul Aziz University,
- 2003 Medical Applied Sciences, Jeddah, Saudi Arabia.



EXPERIENCE

- Present Work as assistance professor at Majma'ah University,
- 2021 Medical Laboratory Department, Saudi Arabia.
- 2021 Work as a demonstrator at Majma'ah University,
- 2011 Medical Laboratory Department, Saudi Arabia.
- 2011 Worked at King Khaled University hospital,
- 2009 Laboratory Department, Riyadh, Saudi Arabia.
-

SEMINARS, WORKSHOPS, AND CONFERENCES ATTENDANCE

- 18-19 April 2007: 3rd National Applied Medical Sciences Students Meeting .
- 10 December 2006: Annual Clinical Immunology & Allergy Workshop.
- 22-25 march 2004: Saudi international transfusion medicine symposium
- 25-27 November 2006: international Saudi symposium on homeostasis and thrombosis
- 21-23 November 2005: International Saudi Symposium of Pediatric Hematology/Oncology.
- 6 May 2007: Establishing Electronic Policy & Procedure Manual Workshop.
- 13 November 2013. Workshop in nanotechnology, college of Medical Applied sciences, Majmaah University.
- Jan 1st, 2014: The first scientific day, faculty of science, Majmaah University.

TRAINING EXPERIENCES:

- Three months of training in King Fahd Hospital in Jizan, hematology department 2006-2007.
- Three months of training in King Abdul Aziz University Hospital, hematology department. 2006-2007.
- Three months of training in king Abdul Aziz Hospital & oncology center in Jeddah, hematology department 2006-2007.
- Three months Training in king Fahd Research center at King Abdul Aziz University, Genomic Medical Unit

PERSONAL INFORMATION:

Place of birth: Jizan, Saudi Arabia

Date of Birth: November 7, 1984

Nationality Saudi

Gender Male

CONTACTS

☎ +966 503095462

✉ Y.madkhali@mu.edu.sa

🌐 Saudi

📍 AlMajma'ah –Saudi Arabia

REFERENCES

Dr. Camille c.ettelaie@hull.ac.uk

Biomedical Science, Hull University, UK.

E-mail: c.ettelaie@hull.ac.uk

Prof. John Greenman

Biomedical Science, Hull University, UK.

E-mail: j.greenman@hull.ac.uk

PUBLICATIONS AND PRESENTATIONS:

- **Madkhali, Y., Rondon, A., Featherby, S., Maraveyas, A., Greenman, J. and Ettelaie, C. (2021) Factor VIIa Regulates the Level of Cell-Surface Tissue Factor through Separate but Cooperative Mechanisms. *Cancers*, 13(15), p.3718.**
- **Madkhali, Y., Featherby, S., Collier, M., Maraveyas, A., Greenman, J. and Ettelaie, C. (2019) The Ratio of Factor VIIa:Tissue Factor Content within Microvesicles Determines the Differential Influence on Endothelial Cells. *TH Open*, 03(02), 132-145.**
- **Featherby, S., Madkhali, Y., Maraveyas, A. and Ettelaie, C. (2019) Apixaban Suppresses the Release of TF-Positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity. *Thrombosis and Haemostasis*, 119(09),1419-1432**
- **Ethaeb, A., Mohammad, M., Madkhali, Y., Featherby, S., Maraveyas, A., Greenman, J. and Ettelaie, C. (2019) Accumulation of tissue factor in endothelial cells promotes cellular apoptosis through over-activation of Src1 and involves β 1-integrin signalling. *Apoptosis*, 25(1- 2),29-41**
- **Madkhali Y, Greenman J, Ettelaie C (2017) The synergy between tissue factor-containing microvesicles and PAR2 activation in the induction of apoptosis is dependent on the properties of the cancer-derived microvesicles (poster). Presented at annual conference of extracellular vesicles. Cambridge, UK.**
 - **Madkhali Y, Maraveyas A, Greenman J, Ettelaie C (2017) Cancer cell-derived microvesicles induce endothelial cell apoptosis mediated through tissue factor, factor VII and PAR2 activation (poster). Presented at the 9th international conference on thrombosis & hemostasis issues in cancer. University of Bergamo, Italy.**
- **Madkhali Y, Greenman J, Ettelaie C (2017) The synergy between tissue factor-containing microvesicles and PAR2 activation in the induction of apoptosis is dependent on the properties of the cancer-derived microvesicles (poster). Presented in BSHT Annual Scientific Meeting. University of Warwick, UK.**
 - **Madkhali Y, Maraveyas A, Greenman J, Ettelaie C (2018) Investigation of Mechanism of Tissue Factor-Mediated Cell Apoptosis (poster). Presented in BSHT Annual Scientific Meeting. University of Warwick, UK**

- **Madkhali Y, Maraveyas A, Greenman J, Ettelaie C (2019) The ratio of factor VIIa:tissue factor content within microvesicles determines the differential influence on endothelial cells (poster). Presented at congress of the international society on thrombosis and haemostasis. Melbourne, Australia**

- **Madkhali Y, Maraveyas A, Greenman J, Ettelaie C (2019) Excess tissue factor is preferentially cleared from endothelial cells through microvesicle release and then, by caveolae-mediated internalisation, through a mechanism requiring fVIIa (poster). Presented at congress of the international society on thrombosis and haemostasis. Melbourne, Australia**

- **Madkhali Y, Maraveyas A, Greenman J, Ettelaie C (2019) The ratio of factor VIIa:tissue factor content within microvesicles determines the differential influence on endothelial cells (poster). Presented at European Congress on Thrombosis and Haemostasis. Glasgow, Scotland.**

- **Madkhali Y, Featherby S, Maraveyas A, Greenman J, Ettelaie C (2018) Cancer Cells Release Active TF-fVIIa Complex Which Can Be Directly Inhibited by Apixaban. Presented in BSHT Annual Scientific Meeting. University of Warwick, UK.**